In summary, we discovered that RAD51 was upregulated in HCC, and RAD51 silencing or inhibition exhibited antitumor and synergistic antitumor activities with sorafenib toward HCC by increasing bulky intracellular DNA damage. This evidence concerns the gene RAD51 and hepatocellular carcinoma.